Media stories about Pluristem Therapeutics (NASDAQ:PSTI) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Pluristem Therapeutics earned a daily sentiment score of 0.18 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.8539378245804 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the media stories that may have impacted Accern Sentiment’s analysis:

Several equities research analysts recently weighed in on the stock. Maxim Group restated a “buy” rating and issued a $2.00 price target on shares of Pluristem Therapeutics in a research report on Tuesday, September 5th. Zacks Investment Research upgraded shares of Pluristem Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 22nd. HC Wainwright restated a “buy” rating and issued a $3.50 price target on shares of Pluristem Therapeutics in a research report on Tuesday, September 19th. ValuEngine upgraded shares of Pluristem Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Monday, October 2nd. Finally, Seaport Global Securities restated a “buy” rating and issued a $5.00 price target on shares of Pluristem Therapeutics in a research report on Friday, October 6th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $4.38.

Pluristem Therapeutics (NASDAQ:PSTI) traded down $0.01 during mid-day trading on Monday, reaching $1.53. 312,800 shares of the company’s stock were exchanged, compared to its average volume of 414,733. Pluristem Therapeutics has a fifty-two week low of $1.04 and a fifty-two week high of $2.12.

Pluristem Therapeutics (NASDAQ:PSTI) last posted its quarterly earnings data on Tuesday, November 14th. The biotechnology company reported ($0.08) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.08). equities research analysts expect that Pluristem Therapeutics will post -0.34 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Watch List News and is owned by of Watch List News. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.watchlistnews.com/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-pluristem-therapeutics-psti-stock-price/1743789.html.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.

Insider Buying and Selling by Quarter for Pluristem Therapeutics (NASDAQ:PSTI)

Receive News & Ratings for Pluristem Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.